Introduction

Objectives
Methods
• The aim of the study was to investigate the prescription (Rx) patterns of Selective Serotonin (Norepinephrine) Reuptake Inhibitors (SS(N)RI) in patients treated by GPs and NPs. 
Data source
• The IMS® LRx database served to identify eligible patients (5) • Contains around 60% of prescriptions reimbursed by statutory health insurance funds • Reflects the actual dispensation of drugs • Full product information and prescription information are available
Study population
Statistical analyses
• The primary outcome was the proportion of patients that received Rx from both a GP and a NP • Cox regression model evaluating age, gender, substance, type of physician and previous prescription of other antidepressants • Kaplan-Meier plots were created to visualize the associations • Depression is common health issue in Germany, with an overall prevalence of 8.1 patients per 100 persons ( 1 ) • The most commonly prescribed pharmaceutical treatment prescribed in Europe are the selective serotonin (norepinephrine) reuptake inhibitors (ss(n)ri) (2, 3).
• The German health system accepts treatment of depression by both general practitioners (GP) and Neurologists/psychiatrists (NP) (4).
• It unknown how much GPs are involved in the treatment of depression in Germany and if patients receive treatment from both specialties. • The majority of the patients (60%) received their initial ss(n)ri from a GP indicating that the GP plays an important role in the treatment of depression in Germany.
Inclusion Exclusion
• Future studies should therefore also focus on the role of GPs in the treatment of depression.
Conclusions
Results
• The majority of patients received the first Rx from a GP (58.6%). There were slight differences in the baseline characteristics of the two patient cohorts (tabel1) • Over one third of patients (36.1%) of patients initially treated by a GP and 30% of patients initially treated by a NP, received only 1 Rx.
• Of the patients who received at least two prescriptions, 26.3% switched prescriber during follow-up (24.5% of patients initially treated by a GP and 28.4% of patients initially treated by a NP.
• Switching prescriber was more likely if a patient received the initial prescription by a NP, if patients are younger at index and for those who received previous prescriptions for AD. The likelihood was also higher for patients starting on Sertraline and Venlafaxine 
